Insights on carbapenem-resistant Pseudomonas aeruginosa

Pseudomonas aeruginosa (P. aeruginosa) is ubiquitous in nature, and may be a causative agent severe, life-threatening infections. In >60% of cases, β-lactam antibiotics are used the therapy P. infections, therefore emergence carbapenem-resistant (CRPA) significant clinical concern. this study, phenotypic methods were to characterize fifty-four (n = 54) isolates, which included based on their suspected non-susceptibility meropenem. Minimum inhibitory concentrations (MICs) meropenem, ceftazidime, cefepime, ciprofloxacin, gentamicin, determined using E-tests, while colistin MICs broth microdilution. The isolates subjected modified Hodge test (MHT), carbapenem-inactivation method (mCIM) imipenem/EDTA combined disk (CDT). AmpC efflux pump overexpression was studied agar plates containing cloxacillin phenylalanine-arginine β-naphthylamide (PAβN), respectively. Assessment biofilm-formation carried out crystal violet tube-adherence method. 38.9% strains showed meropenem resistant range (>8 mg/L). Efflux-pump AmpC-hyperproduction seen 44.4% 35.2% 88.8% characterized as strong biofilm-producers. On other hand, presence carbapenemases minority (16.7%) tested isolates. As safe effective therapeutic options Gram-negative infections severely limited, characterization these molecular-based important provide insights into epidemiological features pathogens.